Skip to main content
EVGN
NASDAQ Life Sciences

Evogene Q3 Revenue Collapses to $141K After Bayer Deal Ends, Loss Widens

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.323
Mkt Cap
$6.319M
52W Low
$0.25
52W High
$1.26
52W Position info
29% above low
Off High info
74% below high
Rel. Volume
Market data snapshot near publication time

EVGN sits 29% above its 52-week low of $0.25.

Summary

Q3 revenue came in at $141,000 against a $365,000 consensus — a steep miss driven by the May 2026 conclusion of the Bayer license and collaboration agreement. The company swung to a net loss from prior-year net income, with R&D costs up on the absence of prior-year grants and FX, while sales and marketing fell on lower activity at Casterra and AgPlenus. The loss per share of $0.17 was slightly better than the $0.19 consensus, but that is small comfort against a revenue base that has largely evaporated. No financial or operational guidance was given. This lands on top of a rough stretch: the September 28 6-K showed a $7.7M H1 loss and a fully used $3.3M ATM, and the November 16 6-K disclosed chairman Nir Nimrodi's resignation. With the stock at $0.32 and a March 29, 2027 Nasdaq bid-price deadline, the balance sheet and any new financing terms matter more than the P&L line items.

At the time of this announcement, EVGN was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.25 to $1.26. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

EVGN - Latest Insights

EVGN
Nov 16, 2026, 7:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3646
Real-time Price: $0.3233 info
Change: -$0.0413 (-11%) info
Market Cap: $6.319M info
EVGN
Oct 06, 2026, 4:00 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.4101
Real-time Price: $0.3233 info
Change: -$0.0868 (-21%) info
Market Cap: $6.319M info
EVGN
Sep 30, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4168
Real-time Price: $0.3233 info
Change: -$0.0935 (-22%) info
Market Cap: $6.319M info
EVGN
Sep 28, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3907
Real-time Price: $0.3233 info
Change: -$0.0674 (-17%) info
Market Cap: $6.319M info
EVGN
Sep 15, 2026, 5:15 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.5281
Real-time Price: $0.3233 info
Change: -$0.2048 (-39%) info
Market Cap: $6.319M info